The District of Delaware's chief judge recently held in two rulings that companies must have permanent ties to the state to face patent suits there following the U.S. Supreme Court's TC Heartland ruling, and his analysis could keep many generic-drug cases in his court. Here's what attorneys can learn from the decisions.
Bombarded by class action lawsuits over its failed anti-piracy technology, music entertainment giant Sony BMG has tentatively agreed to settle a lawsuit brought by plaintiffs that accused the company of putting consumers’ computers at risk.
2005 was a big year for intellectual property lawsuits, with combined patent, copyright and trademark cases jumping 14% over 2004, according to a survey conducted by IP Law Bulletin. But behind those numbers is a surprising trend: patent litigation is on the decline in the U.S., while copyright litigation is exploding thanks to aggressive enforcement actions by the entertainment industry.
Amid a wave of litigation over lucrative flat-panel display technology, Hong Kong electronics maker Proview and Japanese rival Hitachi have settled a U.S. lawsuit brought by Hitachi over LCD monitor patents.
Baxter Healthcare Corp. has ignored an appeal by rival Abbott Laboratories to launch at risk a generic version of Abbot’s popular inhaled anesthetic Ultane in the United States, Europe and Japan in 2006.
Internet search company Google Inc. has been sued for $5 billion for allegedly violating patents for voice over internet protocol (VoIP) technology held by a small patent holding firm.
Apple Computer Inc. is being challenged by a United Kingdom-based company over keyboard technology used in its Mac G4 line of PowerBooks and iBooks.
Semiconductor giant MEMC Electronic Materials Inc. has sued French chip equipment maker Soitec S.A. for violation of MEMC's European patents on defect-free silicon, or “perfect Silicon”.
Finish mobile phone maker Nokia Corp. has lost its final bid to avoid paying a $252 million award to wireless technology firm InterDigital Communications Corp. to settle drawn-out arbitration between the two rivals.
Cargill Inc.’s patent challenge against Dow Chemical Co. deflated once again in federal court after a jury found Cargill had withheld information from the U.S. Patent and Trademark Office.
Following a four-year skirmish, a patent held by 3M Co. was found to be valid in federal court after being challenged by a competitor.
Texas Attorney General Greg Abbott has expanded his lawsuit against Sony BMG Music Entertainment in the wake of a spyware scandal surrounding the music publisher’s failed anti-piracy technology on music CDs.
Just days before Christmas, the Christian evangelical group Jews for Jesus Inc. sued Google Inc. in federal court, accusing the search engine powerhouse of trademark infringement in one of its 8 billion web pages.
Pharmaceutical company Cephalon Inc. dropped its lawsuit Thursday against generic drug maker Ranbaxy Laboratories Ltd. over the sleeping disorder treatment Provigil.
A federal appeals court has reversed a lower court decision that deemed invalid several skincare patents, in a case that pitted a celebrity doctor and best-selling author against a pharmaceutical corporation.
After a six-year feud over a potential blockbuster drug, a small family-owned pharmaceutical company has been awarded $48 million from a biotechnology firm accused of illegally licensing its patents.
The U.S. International Trade Commission has launched an investigation into a Canadian company’s possible infringement of patents held by medical device maker Varian Medical Systems.
In a victory for Johnson & Johnson, the U.S. Court of Appeals for the Federal Circuit affirmed a lower court’s ruling preventing drug maker Mylan Laboratories Inc. from duplicating its lucrative anti-infective drug Levaquin.
Electronics maker Honeywell International has filed another suit in its quest to protect its intellectual property covering LCD technology, this time targeting Citizen Watch Co.
Pfizer's victory in the Lipitor trial may bring a chill to the generic drug industry, which has been increasingly bold in its legal maneuvers in recent years.
Extending the drawn-out legal row over generic Wellbutrin, a subsidiary of Andrx Pharmaceuticals LLC has sued British rival GlaxoSmithKline PLC, alleging the company’s current formula for the antidepressant infringes Andrx’s patent.